Keapstone Therapeutics' Unattributed Round

Keapstone Therapeutics raised a round of funding on , .

Keapstone Therapeutics is developing a series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson's and amyotrophic lateral sclerosis (ALS).…

Articles about Keapstone Therapeutics' Unattributed Round: